🇺🇸 FDA
Pipeline program

RMC-6291

RMC-LUNG-101

Phase 2 small_molecule active

Quick answer

RMC-6291 for Non-Small Cell Lung Cancer, NSCLC is a Phase 2 program (small_molecule) at Revolution Medicines with 2 ClinicalTrials.gov record(s).

Program details

Company
Revolution Medicines
Indication
Non-Small Cell Lung Cancer, NSCLC
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials